LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
TaiGen and TTY Biopharm jointly develop and commercialize a novel topoisomerase I inhibitor for cancer treatment
TaiGen Biotechnology Co., Ltd. and TTY Biopharm Co., Ltd. have announced the signing of an agreement to jointly develop and market a novel topoisomerase I inhibitor, DB67, for cancer treatment.

DB67, the lead compound of a series of topoisomerase I inhibitors, was discovered and patented by the researchers at the University of Pittsburgh, USA. National Health Research Institutes (NHRI) of Taiwan, through funding from the Ministry of Economic Affairs (MOEA) and with an aim to help accelerate new drug development by the local pharmaceutical industry, has licensed the Asian rights (including Japan) of DB67 and assigned them to TTY for development and commercialization. DB67 has shown potent activities in various preclinical tumor models and, due to its physical property, has a great potential to treat brain malignancy. The current MOEA funding will cover almost all the cost before phase I clinical trials. MOEA could also fund up to 40% for phase I and II trials and up to 25% for phase III trials for selected drug candidates.

Under the terms of the agreement, TaiGen and TTY will be responsible for conducting studies based on each party's experience and expertise. TaiGen's responsibilities will include areas of animal disease models, pharmacokinetics, drug metabolism, and toxicology. TTY's responsibilities include formulation, GMP production of dosage forms, and organization of clinical trials. TaiGen and TTY have a plan in place to market the drug jointly in Asia. The financial terms of the agreement were not disclosed.

Dr. Ming-Chu Hsu, President & CEO of TaiGen, said, “We are very pleased to partner with TTY Biopharma, a leading Taiwanese pharmaceutical company, for the development and commercialization of DB67, a promising drug candidate with proven mechanism of action. TaiGen and TTY clearly have complementary strengths that can accelerate drug development. The GLP toxicology studies are underway and filing of IND is planned for 4Q 2014. This agreement endorses the value of our drug discovery and development capabilities and enriches our pipeline that currently consists of several candidates in preclinical development. We look forward to a fruitful collaboration with TTY.”

TaiGen Biotechnology is a privately held pharmaceutical company based in Taiwan with a vision to become a fully integrated global pharmaceutical company. The company's areas of therapeutic focus include oncology, chronic inflammation and viral infection. TaiGen has strong financial backing with series-A financing of US$ 37 millions US dollars in July, 2001, led by MPM Capital, the world largest biotech venture firm, along with the Taiwanese government and top-tier Taiwanese investors. The company is building an innovative product pipeline through in-house discovery programs and in-license of development candidates. TaiGen's strategic partners include Arena Pharmaceuticals of USA — for the application of constitutively-activated receptor technology (CART) to selected G protein- coupled receptors (GPCRs), Chang Geng Memorial Hospital of Taiwan — for access to tumor and hepatitis tissues from 7,000 patients and discovery of novel drug targets, Fujisawa Pharmaceuticals of Japan — for out-licensing of a CART-GPCR target for discovery of drugs to treat inflammatory diseases, and BioXell of Italy — for collaboration in discovery of novel drug target and therapeutics to treat chronic inflammation. At present, TaiGen has 88 employees including 76 scientists recruited from the US, Europe, Canada and Taiwan. In addition to DB67, the company currently has several lead compounds in preclinical development to treat rheumatoid arthritis, transplant rejection, multiple sclerosis, cancer and stem cell mobilization.

TTY Biopharm, a public company, is one of the top five pharmaceutical companies in Taiwan. The company is focusing on oncology, CV, infection and GI therapeutics. The core strengths of TTY include late stage development (formulation and clinical studies) as well as brand marketing of new drugs.

TTY aims to be the best strategic partner of international biopharmaceutical companies for clinical studies and marketing in Asia. In the next five years, TTY plans to become a leader in anti-cancer drug development and have the most innovative formulation technology in Asia.

Source: TaiGen Biotechnology Co., Ltd.

Click here for the complete issue.

news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
Asia Pacific Biotech News
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
Obesity / Outlook for 2018
Searching for the fountain of youth
Women in Science - Making a difference
Digestive health in the 21st century - Trust your guts
Dental health - The root to good health
Cancer - Therapies and strategies for better patient outcomes
Water management / Vaccination
Regenerative medicine / Biotech start ups
Digital healthcare / 3D printing
Bones / Breast cancer
Liver health / Top science research nations & institutions
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
About Us
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy